BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma

PURPOSE: NRAS mutations in malignant melanoma are associated with aggressive disease requiring rapid antitumor intervention, but there is no approved targeted therapy for this subset of patients. In clinical trials, the MEK inhibitor (MEKi) binimetinib displayed modest antitumor activity, making com...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Niessner, Heike, Sinnberg, Tobias, Kosnopfel, Corinna, Smalley, Keiran S. M., Beck, Daniela, Praetorius, Christian, Mai, Marion, Beissert, Stefan, Kulms, Dagmar, Schaller, Martin, Garbe, Claus, Flaherty, Keith T., Westphal, Dana, Wanke, Ines, Meier, Friedegund
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5641247/
https://ncbi.nlm.nih.gov/pubmed/28724666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados